x
Filter:
Filters applied
- JTO: Editors Choice
- Chung, Jin-HaengRemove Chung, Jin-Haeng filter
- Brambilla, ElisabethRemove Brambilla, Elisabeth filter
- Yatabe, YasushiRemove Yatabe, Yasushi filter
Publication Date
Please choose a date range between 2014 and 2021.
Author
- Beasley, Mary Beth3
- Dacic, Sanja3
- Hirsch, Fred R3
- Kerr, Keith M3
- Nicholson, Andrew G3
- Noguchi, Masayuki3
- Pelosi, Giuseppe3
- Thunnissen, Erik3
- Borczuk, Alain2
- Botling, Johan2
- Bubendorf, Lukas2
- Chen, Gang2
- Chou, Teh-Ying2
- Cooper, Wendy A2
- Daigneault, Jillian B2
- Hwang, David2
- Jain, Deepali2
- Lantuejoul, Sylvie2
- Lin, Dongmei2
- Lopez-Rios, Fernando2
- Moreira, Andre L2
- Aisner, Seena1
Editors Choice
3 Results
- Original Article Translational OncologyOpen Archive
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
Journal of Thoracic OncologyVol. 16Issue 4p686–696Published online: March 1, 2021- Mari Mino-Kenudson
- Nolwenn Le Stang
- Jillian B. Daigneault
- Andrew G. Nicholson
- Wendy A. Cooper
- Anja C. Roden
- and others
Cited in Scopus: 7Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four assays have been approved/ Communauté Européene–In vitro Diagnostic (CV-IVD)–marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs). - Review ArticleOpen Archive
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Journal of Thoracic OncologyVol. 15Issue 9p1409–1424Published online: June 6, 2020- Lynette M. Sholl
- Fred R. Hirsch
- David Hwang
- Johan Botling
- Fernando Lopez-Rios
- Lukas Bubendorf
- and others
Cited in Scopus: 115Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. - Original ArticlesOpen Archive
Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study
Journal of Thoracic OncologyVol. 9Issue 9p1354–1362Published in issue: September, 2014- Erik Thunnissen
- Masayuki Noguchi
- Seena Aisner
- Mary Beth Beasley
- Elisabeth Brambilla
- Lucian R. Chirieac
- and others
Cited in Scopus: 33The 2004 World Health Organization classification of lung cancer contained three major forms of non–small-cell lung cancer: squamous cell carcinoma (SqCC), adenocarcinoma (AdC), and large cell carcinoma. The goal of this study was first, to assess the reproducibility of a set of histopathological features for SqCC in relation to other poorly differentiated non–small-cell lung cancers and second, to assess the value of immunohistochemistry in improving the diagnosis.